The US Food and Drug Administration (FDA) has approved deuruxolitinib an oral Janus Kinase (JAK) inhibitor, for the treatment of severe alopecia areata in adults. The drug's approval is based on the results of two Phase 3 clinical trials, THRIVE-AA1 (NCT04518995) and THRIVE-AA2 (NCT04797650), which collectively included 1,220 patients with at least 50% scalp hair loss as assessed by the Severity of Alopecia Tool (SALT).